Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Separation or purification
Reexamination Certificate
1994-06-17
2001-09-04
Schwartzman, Robert A. (Department: 1636)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Separation or purification
C530S412000, C530S415000, C530S416000, C530S421000
Reexamination Certificate
active
06284874
ABSTRACT:
FIELD OF THE INVENTION
The present invention relates to the purification of a serine proteinase inhibitor, &agr;
1
-proteinase inhibitor.
BACKGROUND OF THE INVENTION
Alpha
1
-Proteinase Inhibitor (&agr;
1
-PI), also known as &agr;
1
-antitrypsin, is a serum glycoprotein with a molecular weight of 52,000. Alpha
1
-PI is synthesized in the liver and is present in the serum at levels between 150 and 350 mg/dl (equivalent to 30-80 &mgr;M) when assayed with plasma standards.
Alpha
1
-PI functions in the lungs to inhibit neutrophil elastase, a serine protease, which in large quantities can lead to the destruction of the alveolar walls. In the normal lung, &agr;
1
-PI provides more than 90% of the anti-neutrophil elastase protection in the lower respiratory tract.
Alpha
1
-PI deficiency is an autosomal, recessive hereditary disorder displayed by a large number of allelic variants and has been characterized into an allelic arrangement designated as the protease inhibitor (Pi) system. These alleles have been grouped on the basis of the &agr;
1
-PI levels that occur in the serum of different individuals. Normal individuals have normal serum levels of &agr;
1
-PI (normal individuals have been designated as having a PiMM phenotype). Deficient individuals have serum &agr;
1
-PI levels of less than 35% of the average normal level (these individuals have been designated as having a PiZZ phenotype). Null individuals have undetectable &agr;
1
-PI protein in their serum (these individuals have been designated as having a Pi(null)(null) phenotype).
Alpha
1
-PI deficiency is characterized by low serum (less than 35% of average normal levels) and lung levels of &agr;
1
-PI. These deficient individuals have a high risk of developing panacinar emphysema. This emphysema predominates in individuals who exhibit PiZZ, PiZ(null) and Pi(null) (null) phenotypes. Symptoms of the condition usually manifests in afflicted individuals in the third to fourth decades of life.
The emphysema associated with &agr;
1
-PI deficiency develops as a result of insufficient &agr;
1
-PI concentrations in the lower respiratory tract to inhibit neutrophil elastase, leading to destruction of the connective tissue framework of the lung parenchyma. Individuals with &agr;
1
-PI deficiency have little protection against the neutrophil elastase released by the neutrophils in their lower respiratory tract. This imbalance of protease:protease inhibitor in &agr;
1
-PI deficient individuals results in chronic damage to, and ultimately destruction of the lung parenchyma and alveolar walls.
Individuals with severe &agr;
1
-PI deficiency typically exhibit endogenous serum &agr;
1
-PI levels of less than 50 mg/dl, as determined by commercial standards. Individuals with these low serum &agr;
1
-PI levels have greater than an 80% risk of developing emphysema over a lifetime. It is estimated that at least 40,000 patients in the United States, or 2% of all those with emphysema, have this disease resulting from a defect in the gene coding for &agr;
1
-PI. A deficiency in &agr;
1
-PI represents one of the most common lethal hereditary disorders of Caucasians in the United States and Europe.
Therapy for patients with &agr;
1
-PI deficiency is directed towards replacement or augmentation of &agr;
1
-PI levels in the serum. If serum levels of &agr;
1
-PI are increased, this is expected to lead to higher concentrations in the lungs and thus correct the neutrophil elastase:&agr;
1
-PI imbalance in the lungs and prevent or slow destruction of lung tissue. Studies of normal and &agr;
1
-PI deficient populations have suggested that the minimum protective serum &agr;
1
-PI levels are 80 mg/dl or 11 &mgr;M (about 57 mg/dl; using pure standards). Consequently, most augmentation therapy in &agr;
1
-PI deficient patients is aimed toward providing the minimum protective serum level of &agr;
1
-PI, since serum &agr;
1
-PI is the source of alveolar &agr;
1
-PI.
Alpha
1
-PI preparations have been available for therapeutic use since the mid 1980's. The major use has been augmentation (replacement) therapy for congenital &agr;
1
-PI deficiency. The half-live of human &agr;
1
-PI in vivo is 4.38 days with a standard deviation of 1.27 days. The currently recommended dosage of 60 mg &agr;
1
-PI/kg body weight weekly will restore low serum levels of &agr;
1
-PI to levels above the protective threshold level of 11 &mgr;M or 80 mg/dl.
Previously &agr;
1
-PI has been purified by various techniques. One such process combined chromatography on an anion-exchange chromatography medium followed by PEG precipitation. Other purification procedures have used PEG precipitation followed by anion-exchange chromatography and others have used multiple PEG precipitation steps followed by anion-exchange chromatography. Still other methods have used phase separation techniques to purify &agr;
1
-PI. Specific activities of 1.26 units/mg have been reported for purified &agr;
1
-PI.
SUMMARY OF THE INVENTION
The present invention is directed to a process for purifying a,-proteinase inhibitor. The process comprises providing an impure protein fraction which comprises &agr;
1
-proteinase inhibitor. The impure protein fraction is precipitated with a precipitant comprising PEG. In a preferred embodiment the precipitant further comprises ZnCl
2
. The supernatant from the PEG precipitation, which comprises &agr;
1
-proteinase inhibitor is collected and applied to an anion-exchange medium. A fraction comprising &agr;
1
-proteinase inhibitor is recovered from the anion-exchange medium and applied to a metal chelate medium. A fraction comprising &agr;
1
-proteinase inhibitor is then recovered from the metal chelate medium. In a preferred embodiment the fraction comprising &agr;
1
-proteinase inhibitor recovered from the metal chelate medium is further purified by chromatography on a second ion-exchange medium.
Alpha
1
-proteinase inhibitor purified by the process has a specific activity greater than 0.6 units/mg.
DETAILED DESCRIPTION
The present invention describes a purification process for the purification of &agr;
1
-PI. This purification procedure uses a unique combination of known purification steps to produce a high specific activity &agr;
1
-PI preparation.
Alpha
1
-Proteinase Inhibitor Purification
Alpha
1
-PI is purified from an impure protein fraction. The impure protein fraction may be plasma, &agr;
1
-PI produced by recombinant methods or any other source comprising &agr;
1
-PI protein. In a preferred embodiment &agr;
1
-PI is prepared from frozen plasma. The plasma is thawed and the Cohn IV
1
+IV
4
fraction is prepared. The preparation of the Cohn IV
1
+IV
4
fraction (the Cohn IV
1
+IV
4
precipitate) is well known in the art and is described briefly here.
Preparation of IV
1
+IV
4
Fraction
Plasma is maintained at a temperature of 1.5° C. ±1.5° C. and the pH is adjusted to 7±0.2 with either sodium bicarbonate or acetate buffer, pH 4.0. Sufficient cold SD3A ethanol (95% v/v ethanol and 5% v/v methanol) is added to bring the plasma to a final alcohol concentration of 8% v/v. During the alcohol addition the temperature of the plasma is lowered to −2° C.±1° C. The precipitate which forms is removed by centrifugation in a Sharples or Westphalia centrifuge or by filtration through a filter press, at −2° C.±1° C. The result precipitate and supernatant are designated the Fraction I precipitate and supernatant.
The Fraction I supernatant is adjusted to pH 6.9±0.1 by the addition of pH 4 acetate buffer (0.8 M sodium acetate adjusted to pH 4 with acetic acid) and is brought to 20% v/v alcohol by the addition of cold SD3A alcohol. During the alcohol addition the temperature is lowered to −5.5° C.±1.5° C. The precipitate which forms is removed by centrifugation in a Sharples or Westphalia centrifuge or by filtration through a filter press, at −5.5° C.±1.5° C. The result precipitate and supernatant are designated the Fraction II+III precipitate and supernatant.
If required, the Fraction II+
Bhattacharya Prabir
Rolf John M.
Taniguchi T. (Tom)
Uemura Yahiro (Roy)
Alpha Therapeutic Corporation
Christie Parker & Hale LLP
Schwartzman Robert A.
LandOfFree
Process for separating &agr;1-proteinase inhibitor from cohn... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Process for separating &agr;1-proteinase inhibitor from cohn..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Process for separating &agr;1-proteinase inhibitor from cohn... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2514076